The recent upgrade to Overweight by Cantor Fitzgerald analyst Pete Stavropoulos signifies a notable shift in sentiment towards Alector ALEC. This upgrade comes after a series of mixed ratings, including a downgrade to Neutral from Overweight by the same firm in late 2025. The upgrade reflects a more favorable outlook for the company, potentially driven by recent developments in its clinical-stage biotechnology pipeline aimed at treating neurodegenerative diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.